Berenberg analyst Zhiqiang Shu lowered the firm’s price target on Seagen to $170 from $183 and keeps a Buy rating on the shares. The analyst recently met with management and came away with a positive outlook for the company. The firm views Seagen as a mature mid-cap biotech company on a path to becoming a large-cap. In 2023, it expects multiple catalysts including key trial readouts and regulatory decisions.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SGEN:
- Biotech Alert: Searches spiking for these stocks today
- Seagen label for Tukysa in CRC broader-than-expected, says William Blair
- Seagen announces FDA accelerated approval of TUKYSA-trastuzumab combo
- Pieris Pharmaceuticals announces $5M milestone from Seagen
- Seagen, Astellas and Merck announce FDA acceptance of sBLA in urothelial cancer
